Curis
CRIS
£1.36
Share price
-1.09%
Change (1 day)
-71.04%
Change (1 year)
Categories
Operating Margin for Curis (CRIS)
Operating Margin as of July 2025 (TTM): -397.77%
According to Curis's latest financial reports and stock price the company's current Operating Margin is -397.77%. At the end of 2024 the company had an Operating Margin of -397.77%.
Operating Margin history for Curis from 2001 to 2025
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2024 | -397.77% | -15.91% |
| 2023 | -473.04% | -15.18% |
| 2022 | -557.69% | 30.71% |
| 2021 | -426.67% | 54.57% |
| 2020 | -276.03% | -14.08% |
| 2019 | -321.28% | 2.85% |
| 2018 | -312.38% | -42.01% |
| 2017 | -538.66% | -32.88% |
| 2016 | -802.59% | 7.2% |
| 2015 | -748.68% | 293.47% |
| 2014 | -190.28% | 131.66% |
| 2013 | -82.14% | -15.09% |
| 2012 | -96.73% | 44.84% |
| 2011 | -66.78% | 140.91% |
| 2010 | -27.72% | -76.29% |
| 2009 | -116.94% | -25.43% |
| 2008 | -156.81% | 206.87% |
| 2007 | -51.10% | -24.1% |
| 2006 | -67.32% | -74.53% |
| 2005 | -264.35% | -16.21% |
| 2004 | -315.48% | 251.65% |
| 2003 | -89.72% | -78.26% |
| 2002 | -412.69% | -94.52% |
| 2001 | -7,534.60% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Exelixis EXEL | 36.45% | -109.16% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | -14.09% | -96.46% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | -109.76% | -72.41% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -2,248.76% | 465.34% | 🇺🇸 USA |
 Pfizer PFE | 12.60% | -103.17% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 12.82% | -103.22% | 🇺🇸 USA |
 Cel-Sci
CVM | -388.94% | -2.22% | 🇺🇸 USA |
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.